Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study | Zendy

Sean Emery | Zendy; Jacqueline Neuhaus | Zendy; Andrew Phillips | Zendy; Abdel Babiker | Zendy; Calvin Cohen | Zendy; José M. Gatell | Zendy; Pierre Marie Girard | Zendy; Birgit Grund | Zendy; Matthew Law | Zendy; Marcelo Losso | Zendy; Adrian Palfreeman | Zendy; Robin Wood | Zendy

Open Access

Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study

Author(s) -

Sean Emery,

Jacqueline Neuhaus,

Andrew Phillips,

Abdel Babiker,

Calvin Cohen,

José M. Gatell,

Pierre Marie Girard,

Birgit Grund,

Matthew Law,

Marcelo Losso,

Adrian Palfreeman,

Robin Wood

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/586713

Subject(s) - medicine , hazard ratio , antiretroviral therapy , confidence interval , art therapy , viral load , human immunodeficiency virus (hiv) , immunology , physical therapy

The SMART study randomized 5,472 human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts >350 cells/microL to intermittent antiretroviral therapy (ART; the drug conservation [DC] group) versus continuous ART (the viral suppression [VS] group). In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research